← Search & browse all drugs

rizatriptan

N02CC04

Forms & Strengths

Oral tablet: 5 mg, 10 mg
Orally disintegrating tablet (ODT): 5 mg, 10 mg

Adult Dosing

Acute migraine: 5 mg or 10 mg orally as a single dose
Repeat dose if necessary after a minimum of 2 hours
Maximum daily dose: 30 mg in a 24-hour period
Reduce max dose to 5 mg (max 15 mg/24h) in patients taking propranolol

Pediatric Dosing

Ages 6 to 17 years, weight < 40 kg: 5 mg oral tablet or ODT as a single dose
Ages 6 to 17 years, weight >= 40 kg: 10 mg oral tablet or ODT as a single dose
Maximum dose: 1 dose per 24-hour period

Indications

Acute treatment of migraine attacks with or without aura in adults and pediatric patients aged 6 to 17 years

Mechanism of Action

Selective agonist for serotonin (5-HT1B/1D) receptors on intracranial blood vessels and sensory nerves
Causes vasoconstriction of dilated cerebral blood vessels
Inhibits pro-inflammatory neuropeptide release from trigeminal nerve endings

Contraindications

History of ischemic coronary artery disease, vasospastic angina, or other significant underlying cardiovascular disease
Cerebrovascular disease (stroke, TIA) or peripheral vascular disease
Uncontrolled hypertension
Hemiparetic or basilar migraine
Concurrent administration of monoamine oxidase-A (MAO-A) inhibitors or use within 2 weeks of discontinuation
Administration within 24 hours of another 5-HT1 agonist or ergotamine-containing medication

Adverse Reactions

Dizziness
Somnolence
Asthenia/fatigue
Nausea
Chest pain, tightness, or pressure (rarely cardiac ischemia)
Paresthesias

Drug Interactions

Propranolol: increases rizatriptan AUC by 70%; requires dosage adjustment
MAO-A inhibitors: significantly increase rizatriptan concentrations and risk of toxicity
Ergot-containing drugs: additive vasoconstrictive effects; avoid within 24 hours
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): risk of serotonin syndrome

Curated Content: Needs Vetting Before Put to Clinical Use